A novel potent synthetic steroidal liver X receptor agonist lowers plasma cholesterol and triglycerides and reduces atherosclerosis in LDLR-/- mice

British Journal of Pharmacology

Volumn 162, Issue 8, 2011, Pages 1792-1804

  Peng, Dacheng ^a   Hiipakka, Richard A ^a   Xie, Jing Tian ^a   Dai, Qing ^a   Kokontis, John M ^a   Reardon, Catherine A ^b   Getz, Godfrey S ^b   Liao, Shutsung ^a,c  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c NONE   (United States)

Author keywords

adverse effects; agonist; atherosclerosis; cholesterol; liver X receptor; triglyceride

Indexed keywords

3ALPHA, 6ALPHA 24 TRIHYDROXY 22 EN 24, 24 DI(TRIFLUOROMETHYL)5BETA CHOLANE; ACETYL COENZYME A CARBOXYLASE; ANTILIPEMIC AGENT; AT 111; CHOLESTEROL; FATTY ACID SYNTHASE; LIPOPROTEIN; LIVER X RECEPTOR AGONIST; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE; STEROL REGULATORY ELEMENT BINDING PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ABCA1 GENE; ABCG1 GENE; ABCG5 GENE; ABCG8 GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOE GENE; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; INTESTINE; LIPID METABOLISM; LIPOGENESIS; MALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 79953045767     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01202.x     Document Type: Article

References (30)

1. A-Gonzalez N, Bensinger SJ, Hong C, Beceiro S, Bradley MN, Zelcer N, et al,. (2009). Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity 31: 245-258.
2. Adams CM, Reitz J, De Brabander JK, Feramisco JD, Li L, Brown MS, et al,. (2004). Cholesterol and 25-hydroxycholesterol inhibit activation of SREBPs by different mechanisms, both involving SCAP and Insigs. J Biol Chem 279: 52772-52780. (Pubitemid 39656653)
3. Albers M, Blume B, Schlueter T, Wright MB, Kober I, Kremoser C, et al,. (2006). A novel principle for partial agonism of liver X receptor ligands. Competitive recruitment of activators and repressors. J Biol Chem 281: 4920-4930. (Pubitemid 43847754)
4. Bensinger SJ, Tontonoz P, (2008). Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 454: 470-477.
5. Bligh EG, Dyer WJ, (1959). A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37: 911-917.
6. Bradley MN, Hong C, Chen M, Joseph SB, Wilpitz DC, Wang X, et al,. (2007). Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE. J Clin Invest 117: 2337-2346. (Pubitemid 47219578)
7. Brown MS, Faust JR, Goldstein JL, Kaneko I, Endo A, (1978). Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase. J Biol Chem 253: 1121-1128. (Pubitemid 8288831)
8. Cao G, Liang Y, Jiang XC, Eacho PI, (2004). Liver X receptors as potential therapeutic targets for multiple diseases. Drug News Perspect 17: 35-41. (Pubitemid 38419370)
9. Castrillo A, Díaz-Guerra MJ, Hortelano S, Martín-Sanz P, Boscá L, (2000). Inhibition of IkappaB kinase and IkappaB phosphorylation by 15-deoxy-Delta(12,14)-prostaglandin J(2) in activated murine macrophages. Mol Cell Biol 20: 1692-1698. (Pubitemid 30100188)
10. Castrillo A, Joseph SB, Vaidya SA, Haberland M, Fogelman AM, Cheng G, et al,. (2003). Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol Cell 12: 805-816. (Pubitemid 37352775)
11. Chakravarthy MV, Pan Z, Zhu Y, Tordjman K, Schneider JG, Coleman T, et al,. (2005). 'New' hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis. Cell Metab 1: 309-322. (Pubitemid 43977168)
12. Gao ZG, Choi HG, Shin HJ, Park KM, Lim SJ, Hwang KJ, et al,. (1998). Physicochemical characterization and evaluation of a microemulsion system for oral delivery of cyclosporine A. Int J Pharm 161: 75-86.
13. Grefhorst A, Elzinga BM, Voshol PJ, Plösch T, Kok T, Bloks VW, et al,. (2002). Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J Biol Chem 277: 34182-34190.
14. Horton JD, Goldstein JL, Brown MS, (2002). SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109: 1125-1131. (Pubitemid 34496588)
15. Kölsch H, Ludwig M, Lütjohann D, Rao ML, (2001). Neurotoxicity of 24-hydroxycholesterol, an important cholesterol elimination product of the brain, may be prevented by vitamin E and estradiol-17beta. J Neural Transm 108: 475-488. (Pubitemid 32703896)
16. Kratzer A, Buchebner M, Pfeifer T, Becker TM, Uray G, Miyazaki M, et al,. (2009). Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia. J Lipid Res 50: 312-326.
17. Lemaire-Ewing S, Prunet C, Montange T, Vejux A, Berthier A, Bessède G, et al,. (2005). Comparison of the cytotoxic, pro-oxidant and pro-inflammatory characteristics of different oxysterols. Cell Biol Toxicol 21: 97-114. (Pubitemid 41253203)
18. Lo JC, Wang Y, Tumanov AV, Bamji M, Yao Z, Reardon CA, et al,. (2007). Lymphotoxin beta receptor-dependent control of lipid homeostasis. Science 316: 285-288. (Pubitemid 46633106)
19. Peng D, Hiipakka RA, Dai Q, Guo J, Reardon CA, Getz GS, et al,. (2008). Antiatherosclerotic effects of a novel synthetic tissue-selective steroidal liver X receptor agonist in low-density lipoprotein receptor-deficient mice. J Pharmacol Exp Ther 327: 332-342.
20. Peng D, Hiipakka RA, Reardon CA, Getz GS, Liao S, (2009). Differential anti-atherosclerotic effects in the innominate artery and aortic sinus by the liver X receptor agonist T0901317. Atherosclerosis 203: 59-66.
21. Peng D, Hiipakka RA, Xie JT, Reardon CA, Getz GS, Liao S, (2010). Differential effects of activation of liver X receptor on plasma lipid homeostasis in wild-type and lipoprotein clearance-deficient mice. Atherosclerosis 208: 126-133.
22. Phelan CA, Weaver JM, Steger DJ, Joshi S, Maslany JT, Collins JL, et al,. (2008). Selective partial agonism of liver X receptor alpha is related to differential corepressor recruitment. Mol Endocrinol 22: 2241-2249.
23. Quinet EM, Savio DA, Halpern AR, Chen L, Miller CP, Nambi P, (2004). Gene-selective modulation by a synthetic oxysterol ligand of the liver X receptor. J Lipid Res 45: 1929-1942. (Pubitemid 40990886)
24. Quinet EM, Basso MD, Halpern AR, Yates DW, Steffan RJ, Clerin V, et al,. (2009). LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse. J Lipid Res 50: 2358-2370.
25. Radhakrishnan A, Ikeda Y, Kwon HJ, Brown MS, Goldstein JL, (2007). Sterol-regulated transport of SREBPs from endoplasmic reticulum to Golgi: oxysterols block transport by binding to Insig. Proc Natl Acad Sci USA 104: 6511-6518. (Pubitemid 47175533)
26. Reardon CA, Blachowicz L, White T, Cabana V, Wang Y, Lukens J, et al,. (2001). Effect of immune deficiency on lipoproteins and atherosclerosis in male apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 21: 1011-1016. (Pubitemid 34168661)
27. Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, et al,. (2000). Role of LXRs in control of lipogenesis. Genes Dev 14: 2831-2838.
28. Song C, Liao S, (2001). Hypolipidemic effects of selective liver X receptor alpha agonists. Steroids 66: 673-681. (Pubitemid 32799194)
29. VanderLaan PA, Reardon CA, Getz GS, (2004). Site specificity of atherosclerosis: site-selective responses to atherosclerotic modulators. Arterioscler Thromb Vasc Biol 24: 12-22. (Pubitemid 38082406)
30. Yasuda T, Grillot D, Billheimer JT, Briand F, Delerive P, Huet S, et al,. (2010). Tissue-specific liver x receptor activation promotes macrophage reverse cholesterol transport in vivo. Arterioscler Thromb Vasc Biol 30: 781-786.